ECMO Machines Companies

The ECMO machines market is projected to reach USD 0.86 billion by 2030 from USD 0.65 billion in 2025, at a CAGR of 5.8% during the forecast period. Cardiopulmonary conditions such as acute respiratory distress syndrome (ARDS), COPD, and advanced heart failure are becoming increasingly prevalent worldwide due to pollution, lifestyle changes, and aging populations. ECMO machines provide advanced life support when mechanical ventilation or drug-based therapies fail, making them indispensable in tertiary care hospitals. For example, ECMO has been crucial in treating ARDS patients unresponsive to high-frequency oscillatory ventilation. According to clinical studies, survival rates significantly improve when ECMO is used as a last-resort intervention. Hospitals across North America and Europe are expanding ECMO-equipped ICUs to manage rising case volumes. This is further accelerated by the increasing number of heart failure patients awaiting transplants, where ECMO serves as a temporary bridge-to-transplant support. The global increase in respiratory and cardiac morbidity directly boosts ECMO adoption as hospitals aim to reduce mortality rates in high-risk patients.

The prominent players in the ECMO machines market are Fresenius Medical Care AG & Co. KGaA (Germany), Getinge AB (Sweden), Medtronic (Ireland), Terumo Corporation (Japan), Nipro Corporation (Japan), LivaNova PLC (UK), Weigao Group Co., Ltd. (China), Abbott Laboratories (US), MicroPort Scientific Corporation (China), Eurosets S.r.l. (Italy), Spectrum Medical Ltd. (UK), Senko Medical Instrument Mfg. Co., Ltd. (Japan), Chalice Medical Ltd. (UK), magAssist Co., Ltd. (China), Braile Biomédica (Brazil), GizmoMed Private Limited (India). These players have adopted various growth strategies, such as product launches, acquisitions, and expansion, to increase their presence and reach in the ECMO machines market.

To know about the assumptions considered for the study download the pdf brochure

In April 2023, Abbott secured two new clearances from the US Food and Drug Administration (FDA) for its acclaimed life support system, particularly the CentriMag Blood Pump. The extended FDA indication allows for longer-term use in adults, depending on extracorporeal membrane oxygenation (ECMO), a vital life support method for those with heart and lung issues. In November 2022, LivaNova PLC announced the receipt of 510(k) clearance from the US Food and Drug Administration (FDA) for its next-generation advanced circulatory support system, LifeSPARC. This approval signifies that the LifeSPARC system meets the criteria set forth by the FDA and can now be used in the US market.

Getinge AB

Getinge AB has positioned itself as a global leader in the ECMO machines market by leveraging its strong portfolio of advanced life support and critical care solutions. The company emphasizes delivering clinically proven, high-quality ECMO systems integrated with user-friendly interfaces and advanced monitoring tools to ensure safety, reliability, and ease of use in critical settings. Getinge’s extensive global distribution network, combined with deep relationships with hospitals and intensive care units, enhances its ability to penetrate diverse markets and expand its customer base. The company strengthens its competitive edge by focusing on continuous innovation, particularly in improving oxygenator efficiency and minimizing complications such as hemolysis. Its commitment to training programs and service support for healthcare professionals further reinforces adoption and customer loyalty. Getinge’s right to win lies in its reputation for quality, strong presence in intensive care, and ability to deliver comprehensive, end-to-end extracorporeal life support solutions that address acute and long-term patient needs.

Medtronic

Medtronic has established a strong foothold in the ECMO machines market by leveraging its expertise in cardiopulmonary support and advanced perfusion technologies. The company focuses on integrating ECMO systems with its broader cardiovascular and critical care portfolio, creating a seamless ecosystem for hospitals and clinicians. It emphasizes innovations that improve patient safety, such as biocompatible coatings, advanced monitoring features, and systems designed to reduce clotting and infection risks. Its vast global presence and strong partnerships with healthcare providers enable wide-scale adoption and trust in its solutions. Additionally, Medtronic invests heavily in training and education programs to build clinician confidence and optimize patient outcomes. The company’s right to win stems from its brand strength, commitment to R&D, and ability to deliver technologically advanced, reliable ECMO systems that align with the growing demand for life-saving extracorporeal support worldwide.

Market Ranking

The global ECMO machines market is highly consolidated, with prominent players accounting for over 70% of the total market share in 2024. Some of the players dominating the market include Fresenius Medical Care AG & Co. KGaA (Germany), Getinge AB (Sweden), Medtronic (Ireland), Terumo Corporation (Japan), and LivaNova PLC (UK).

The prominent players in the ECMO machines market are based in developed regions such as North America, Europe, and the Asia Pacific. However, in the past few years, several smaller players catering to ECMO machines have emerged from niche markets and are competing with global players based on product scope and innovation. The lucrative growth opportunities in the Asia Pacific and Latin American markets are encouraging market players to strengthen their presence in these regions.

Related Reports:

ECMO Machines Market by Product [ECMO Machines, Components (Oxygenators, Pumps, Controllers)], Modality (Venovenous and Arteriovenous ECMO), Patient Type (Adults, Neonates), Application (Respiratory, Cardiac), End User (Hospitals) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com